Michael Conroy

Michael Conroy

Auto-generated profile, based on publicly available information

Michael Conroy

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMichael Conroy
Michael Conroy
JNJarushka Naidoo
Jarushka Naidoo
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

Verified
Journal Article
Open access
PDF file
DCDarren Cowzer
Darren Cowzer
MZMohammed Zameer
Mohammed Zameer
MCMichael Conroy
Michael Conroy
Walter KolchWalter Kolch
Walter Kolch
ADAustin Duffy
Austin Duffy
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.

19 September 2016 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
MCMichael R. Conroy
Michael R. Conroy
TMTabitha G. Moe
Tabitha G. Moe
In this study, we describe the case of a 36-year-old woman who was diagnosed with hepatocellular carcinoma on a background of Fontan procedure for tricuspid atresia. She had worsening heart failure in the months before presentation, and early investigations noted derangement in liver enzymes and hepatomegaly. Liver biopsy confirmed a hepatocellular carcinoma. Hepatocellular carcinoma is a rare but recognised consequence of cardiac cirrhosis in Fontan patients.

27 June 2018 in Journal of the Intensive Care Society
Verified
Journal Article
Open access
MCMichael Conroy
Michael Conroy
JOJohn O’fLynn
John O’fLynn
BMBrian Marsh
Brian Marsh
Elderly patients are frequently considered poor candidates for continuous renal replacement therapy in intensive care units, but with little evidence base. We gathered data regarding patients requiring continuous renal replacement therapy at our institution’s intensive care unit during 2012–2014, and compared outcomes between patients of 75 years or older, and younger patients. Older patients had similar intensive care unit mortality to younger patients (41.5% vs. 36.1%, p = 0.21), but higher hospital mortality (54.2% vs. 44.0%, p = 0.02), and one-year mortality (63.6% vs. 50.6%, p = 0.005). There were no significant differences in dialysis-dependence rates between older and younger patients at intensive care unit discharge (31.9% vs. 35.8%, p = 0.50), and hospital discharge (18.5% vs. 24.2%, 0.32). Rates of new dialysis-dependence between older and younger patients at time of hospital discharge were similar (10.2% vs. 6.0%, p = 0.20). Intensivists should not withhold continuous renal replacement therapy based on age alone. Other factors should be considered in triage of patients for intensive care unit and continuous renal replacement therapy.

16 March 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMichael Conroy
Michael Conroy
PFPatrick M. Forde
Patrick M. Forde

26 July 2017 in Cureus
Verified
Journal Article
Open access
PDF file
MCMichael Conroy
Michael Conroy
MBMitesh J. Borad
Mitesh J. Borad
ABAlan H. Bryce
Alan H. Bryce
Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent.